Potential EU approval of povorcitinib in hidradenitis suppurativa
Incyte expects European regulators to decide on Povorcitinib for Moderate to severe hidradenitis suppurativa in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Incyte Corporation INCY
- Drug
- Povorcitinib
- For
- Moderate to severe hidradenitis suppurativa
- Stage
- Under EMA review
- When
- H2 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Incyte Q2 2026 earnings release anticipates potential approval and launch in the European Union in late-2026.
- Checked
- Checked by a person when it was added
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- INCY headlines on this site
Incyte expects to report results from its Registrational combination study study of Niktimvo (axatilimab) + ruxolitinib for Newly diagnosed chronic graft-versus-host disease in the second half of 2026 (no exact date yet). Registrational combination study is a study designed to support approval.
More details
- Entry
- Niktimvo + ruxolitinib data in newly diagnosed chronic GVHD · Clinical trial results (readout / topline data)
- Drug
- Niktimvo (axatilimab) + ruxolitinib
- For
- Newly diagnosed chronic graft-versus-host disease
- Stage
- Registrational combination study · a study designed to support approval
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Incyte Q2 2026 earnings release: data for the axatilimab + ruxolitinib combination in newly diagnosed chronic GVHD anticipated in the second half of 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- INCY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte expects to report results from its Phase 1 study of INCA033989 for mutCALR myelofibrosis (mono and with ruxolitinib) in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- INCA033989 (mutCALR) Phase 1 data in treatment-naive myelofibrosis · Clinical trial results (readout / topline data)
- Drug
- INCA033989
- For
- mutCALR myelofibrosis (mono and with ruxolitinib)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Jul 28, 2026) lists this among data anticipated in the second half of 2026; the Phase 3 EXCALIBUR-ET2 study in ET was initiated mid-2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: aol.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- INCY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
INCB123667 (CDK2) Phase 3 first-line maintenance ovarian cancer start, expected in the second half of 2026 (no exact date yet). A company milestone for Incyte (INCB123667 for First-line maintenance ovarian cancer): a step in the program rather than a decision or a data readout.
More details
- Entry
- INCB123667 (CDK2) Phase 3 first-line maintenance ovarian cancer start · Company milestone
- Drug
- INCB123667
- For
- First-line maintenance ovarian cancer
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Jul 28, 2026).
- Checked
- Checked by a person when it was added
- Verify it
- Source: investingnews.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- INCY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presents data on INCB161734 for Metastatic PDAC (with mFOLFOX/GemNabP) and mCRC (with cetuximab) at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- INCB161734 (KRAS G12D) Phase 1 PDAC/CRC combo data rapid orals at ESMO 2026 · Data presented at a medical meeting
- Drug
- INCB161734
- For
- Metastatic PDAC (with mFOLFOX/GemNabP) and mCRC (with cetuximab)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Oct 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Jul 28, 2026): ESMO 2026 runs Oct 23-27 in Madrid; exact session dates not given.
- Checked
- Checked by a person when it was added
- Verify it
- Source: investingnews.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- INCY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presents data on INCB123667 for Recurrent epithelial ovarian cancer at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- INCB123667 + bevacizumab recurrent ovarian Phase 1 efficacy data at ESMO 2026 · Data presented at a medical meeting
- Drug
- INCB123667
- For
- Recurrent epithelial ovarian cancer
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Oct 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR; ESMO 2026 is Oct 23-27, Madrid.
- Checked
- Checked by a person when it was added
- Verify it
- Source: investingnews.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- INCY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Incyte presents data on INCA33890 for MSS colorectal cancer at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- INCA33890 first-line MSS CRC Phase 1 combo data at ESMO 2026 · Data presented at a medical meeting
- Drug
- INCA33890
- For
- MSS colorectal cancer
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Oct 2026 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR; ESMO 2026 is Oct 23-27, Madrid. (PR text spells the compound 'INAC33890'.)
- Checked
- Checked by a person when it was added
- Verify it
- Source: investingnews.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- INCY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page